London-listed investment firm Agronomics has confirmed that its portfolio company Meatable will undergo liquidation after failing to secure continued financial backing. All operating activities at the cultivated meat startup will be terminated, and its legal entity dissolved under statutory procedures.
The decision follows an extended period in which Meatable faced multiple operational and financial challenges throughout 2025. Despite efforts to explore strategic options, the company was unable to raise sufficient funding from either existing shareholders or new investors.
“While this outcome is disappointing, we believe the decision has been taken responsibly”
Agronomics, which specializes in investments in cellular agriculture, disclosed that it will write down its £11.9 million carrying value in Meatable to zero. The total investment of £7.9 million represented approximately 8.1% of Agronomics’ net asset value as of 30 September 2025.
Jim Mellon, Executive Chair of Agronomics, stated: “While this outcome is disappointing, we believe the decision has been taken responsibly and in the best interests of all stakeholders. Agronomics continues to actively manage its portfolio and remains focused on supporting its wider portfolio of businesses with strong long-term growth potential.”
Activity did not translate into capital
Prior to the wind-down decision, Meatable had announced several developments in 2025, including a partnership with Pelagen to develop cultivated leather, a joint venture with TruMeat aimed at building a high-volume cultivated meat production facility in Singapore, and the acquisition of Uncommon Bio’s cultivated meat platform. These activities, however, did not translate into sufficient investor confidence to secure the necessary capital for continued operations.
Meatable’s dissolution comes shortly after Believer Meats, another cultivated meat company, ceased operations last week without public explanation
Agronomics currently maintains a portfolio of more than 20 companies focused on developing food and materials traditionally sourced from animals. The firm’s investment strategy targets areas such as sustainability, food security, and human health within the broader cellular agriculture and alternative proteins sector. The firm noted that it remains committed to its existing investments and will continue managing its portfolio in alignment with long-term sectoral developments.
